United States· US:0069-1975_67f1031d-c298-4cf9-9051-bb8f99e56442
Vyndaqel
A medicinal product containing tafamidis meglumine, registered in United States by Pfizer Laboratories Div Pfizer Inc.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- TAFAMIDIS MEGLUMINE
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1100691975404 CARTON in 1 CARTON (0069-1975-40) / 30 BLISTER PACK in 1 CARTON / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0069-1975-12)
- ndc110069-1975-40
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tafamidis meglumine in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVyndaqelAbacus Medicine A/S
- BelgiumTafamidis AB 20 mgAurobindo
- CzechiaVYNDAQELPfizer Europe MA EEIG, Bruxelles
- FranceVYNDAQEL 20 mg, capsule mollePFIZER EUROPE MA EEIG (BELGIQUE)
- CanadaVYNDAQELPFIZER CANADA ULC
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Belgium · Tafamidis Ab
- Spain · Tafamidis Aurovitas, Tafamidis Goibela
- Iceland · Vyndaqel
- Liechtenstein · Vyndaqel
- Luxembourg · Tafamidis Ab
- Norway · Vyndaqel
- Portugal · Tafamidis Generis, Tafamidis Generis Phar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0192b15f-5e4c-4941-b6e7-3b0dfac7e647 GET /v1/drugs/0192b15f-5e4c-4941-b6e7-3b0dfac7e647?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "20",
"substance": "TAFAMIDIS MEGLUMINE",
"productndc": "0069-1975",
"dosage_form": "CAPSULE, LIQUID FILLED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA211996",
"marketing_category": "NDA"
}See everything about tafamidis meglumine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.